Surgicel® (Fibrillar) in Non-variceal UGI Bleeding

NCT ID: NCT02054260

Last Updated: 2014-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess of effect of Surgicel® (Fibrillar) for preventing delayed bleeding after endoscopic hemostasis in non-variceal upper gastrointestinal bleeding

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-variceal Upper Gastrointestinal Bleeding

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Surgicel add therapy

Group Type EXPERIMENTAL

Surgicel

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Surgicel

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with non variceal upper gastrointestinal bleeding proven by esophagogastroduodenoscopy
* Patients with active bleeding (Forrest classification Ia or Ib or IIa)

Exclusion Criteria

* Patients with upper gastrointestinal tract malignancy
* Patients with acute severe illness
* Coagulopathy: liver cirrhosis, thrombocytopenia
* Pregnant women
Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Soonchunhyang University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Su Jin Hong

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Digestive Disease Center and Research Institute, Department of Internal Medicine, Soonchunhyang University College of Medicine

Bucheon-si, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Su Jin Hong, MD, PhD

Role: CONTACT

+82-32-621-5087

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Su Jin Hong, MD, PhD

Role: primary

+82-32-621-5087

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SCHBC_IRB_2013-40

Identifier Type: -

Identifier Source: org_study_id